Abstract
Accumulating data suggest that matrix metalloproteinases (MMPs), in particular MMP-2 and MMP-9, are deleterious after acute ischaemic stroke. A beneficial effect of MMPs in the repairing phases of cerebral ischaemia has also been proposed. This study investigated the relationship between MMP-2 and MMP-9 and stroke subtypes, clinical recovery and haemorrhagic transformation (HT). We measured MMP-9 and MMP-2 plasma levels in 29 patients with ischaemic stroke at days one and seven. MMP-2 levels increased only in lacunar strokes, whilst MMP-9 increased only in patients with more severe stroke. Basal MMP-2 levels were higher in patients with stable or recovering symptoms whilst MMP-9 values at day seven were correlated with worse clinical outcome. No differences related to the presence of HT were found. This study sustains a different behaviour of MMPs after ischaemic stroke. MMP-2 seems to be expressed early and related to better outcome, whilst MMP-9 seems to be late and related to more severe stroke.
Similar content being viewed by others
References
Rosenberg GA (2002) Matrix metalloproteinases in neuroinflammation. Glia 39:279–291
Fatar M, Stroick M, Griebe M, Hennerici M (2005) Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis 20:141–151
Rosenberg GA, Estrada EY, Dencoff JE (1998) Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29:2189–2195
Nelson R (2005) Novel MMP inhibitor has potential for treatment of stroke. Lancet Neurol 4:530
Lapchak PA, Araujo DM (2001) Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents. CNS Drugs 15:819–829
Zhao BQ, Wang S, Kim HY et al (2006) Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 12:441–445
Cunningham LA, Wetzel M, Rosenberg GA (2005) Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 50:329–339
Bamford J, Sandercock P, Dennis M et al (1991) Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337:1521–1526
Adams HP Jr, Bendixen BH, Kappelle LJ et al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41
Brott T, Adams HP Jr, Olinger CP et al (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20:864–870.
Van Swieten JC, Koudstaal PJ, Visser MC et al (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607
Asahi M, Wang X, Mori T et al (2001) Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21:7724–7732
Montaner J, Alvarez-Sabin J, Molina C et al (2001) Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32:1759–1766
Horstmann S, Kalb P, Koziol J et al (2003) Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 34:2165–2170
Montaner J, Molina CA, Monasterio J et al (2003) Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107:598–603
Montaner J, Alvarez-Sabin J, Molina CA et al (2001) Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32:2762–2767
Kim YS, Lee KY, Koh SH et al (2006) The role of matrix metalloproteinase 9 in early neurological worsening of acute lacunar infarction. Eur Neurol 55:11–15
Montaner J, Rovira A, Molina CA et al (2003) Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J Cereb Blood Flow Metab 23:1403–1407
Rosell A, Alvarez-Sabin J, Arenillas JF et al (2005) A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 36:1415–1420
Castellanos M, Leira R, Serena J, Davalos A (2003) Plasma metalloprotinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 34:40–46
Vukasovic I, Tesija-Kuna A, Topic E et al (2006) Matrix metalloproteinases and their inhibitors in different acute stroke subtypes. Clin Chem Lab Med 44:428–434
Clark AW, Krekoski CA, Bou SS et al (1997) Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 238:53–56
Jourquin J, Tremblay E, Decanis N et al (2003) Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur J Neurosci 18:1507–1517
Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827–839
Jian Liu K, Rosenberg GA (2005) Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med 39:71–80
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lucivero, V., Prontera, M., Mezzapesa, D.M. et al. Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke. Neurol Sci 28, 165–170 (2007). https://doi.org/10.1007/s10072-007-0814-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-007-0814-0